- Head of Biotech Private Investments
- Boston
United States, Institutional
Change
As one of the largest and longest-tenured health care investors in the world, we offer both capital and strategic guidance to bring breakthrough biotechnology to the world. Our biotech venture capital experts, with deep scientific backgrounds, partner with remarkable biotech companies that are leading the way with innovations and aiming to raise the bar on standard of care.
Rayzebio: case study
RayzeBio is a biotechnology company focused on developing targeted radiopharmaceutical drugs for solid tumors in cancers. The team prosecutes diverse sets of binders against clinically validated cancer targets through an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis.
Our Private biotech investments
Wellington looks to understand the science and buys into the vision. They want to be a thought partner, not just a provider of capital.
Dr. Axel Hoos is the CEO of Scorpion Therapeutics, a biotech portfolio company that Wellington has invested in. This statement about Wellington reflects a personal opinion that may not be shared by others. There has been no compensation provided for such statements.
The Private biotech team
Meet our biotech venture capital experts with deep scientific backgrounds and an average of 15+ years of investment experience.
- Principal, Biotech Private Investments
- Boston
- Sector Lead, Biotech Private Investments
- Boston
- Sector Lead, Biotech Private Investments
- Boston
Insights
Read our latest research on biotech innovation, the IPO market, and other venture capital trends.
Showing
of
Insights Posts
Video
2 min
Collaboration in practice: Late-stage biotech
Nilesh Kumar, Head of Biotech Private Investing, explores how working with Wellington’s public-market biotech experts helps his team better understand the feasibility of emerging biotech innovations.
2 min
Video
2026-09-30
Video
3 min
Private biotech innovation versus hype
Nilesh Kumar discusses the next generation of biotech disruptors in obesity, autoimmunity, and oncology, focusing on drugs that solve real-world unmet medical needs.
3 min
Video
2026-06-30
Article
6 min
Private biotech market update: IPOs, M&A, and innovation
Our biotech venture capital experts explore the state of the private biotech market, highlighting the potential IPO-market rebound, surge in private M&A, and the focus on clinical-stage opportunities.
6 min
Article
2026-04-29
Video
4 min
Private biotech investing in 2025
Nilesh Kumar, head of biotech private investing, shares his outlook for 2025, weighing headline risk against biotech venture capital's potential tailwinds.
4 min
Video
2026-02-28
Article
5 min
Private biotech: Immunology and inflammation’s third wave
Our experts discuss how I&I is building on industry progress to offer new treatment solutions and interesting opportunities for private biotech investors.
5 min
Article
2025-12-01
Article
7 min
Venture capital outlook for 2025: 5 key trends
Our venture capital experts are encouraged by the healthier environment for venture capital in 2025. In this year's outlook, they explore key themes for the year ahead, including: higher deployment, AI, rebounding IPOs, and impacts of the 2024 election.
7 min
Article
2025-12-31
Article
4 min
Biotech IPOs in 2025: Quantity, quality, and best practices
We explore today's biotech IPO market, highlighting recent market trends, key characteristics for successful biotech IPOs, and best practices to sustain momentum as a public biotechnology company.
4 min
Article
2025-08-31
URL References
Related Insights
News
Stay up to date on Wellington Private Investing news.
-
WSJ Pro Venture Capital: Wellington Management Raises US$476 Million for Second Biotech Venture Fund
-
Co-heads of biotech private investments I-hung Shih and Nilesh Kumar spoke with the Wall Street Journal to discuss the recent US$476M final close of Biomedical Innovation Fund II and how Wellington is a “one-stop shop” for the next generation of innovative biotech companies.
Source: WSJ Pro Venture Capital. Permission required for reproduction.
-
-
-
Wellington Management announces US$476 million final close for Biomedical Innovation II
-
We are excited to announce the final close of Wellington Biomedical Innovation II, which invests in private biotech companies that are developing the next generation of treatments that seek to improve the standard of care in medicine.
-
-
More private investing focus areas
Venture capital
From energy transformation to sustainable cities to next-generation agriculture, we support innovative companies helping to address the impacts of climate change.
To guide late-stage private companies through the finish line and beyond, we leverage our deep industry expertise, resources, and long-term relationships across public and private markets.
Private credit
Deeper dive on biotech venture capital investing
Our team believes late-stage biotech investing is a form of venture capital focused on investing in private biotech companies that are typically within one to four years of IPO or M&A. In our view, VCs that invest in this stage have the potential to access derisked companies with substantial growth potential. Critically, we believe investors in this space need a deep understanding of the science, the macro and regulatory environment, and the quality of management teams.
Our biotech portfolio companies have access to Wellington’s broader expertise, resources, and networks. This collaboration can take many forms, such as leveraging the networks of Wellington’s public-market biotech analysts, hearing insights on the biotech regulatory environment from the firm’s macro strategists, discussing the biotech competitive landscape with investors across the globe, and much more.
In addition, portfolio companies can partner with our Value Creation Team, which tailors resources to meet companies where they are, help them reach their next stage of growth, and support their long-term success.
Our late-stage biotechnology team accesses a wide range of innovations across the biotech industry, including immunology and inflammation, radiopharmaceuticals, antibody drug conjugates, and improved versions of approved therapeutics (e.g., more convenient dosing or route of administration).
This reflects substantially all portfolio company investments made by Wellington Management’s dedicated private equity portfolios. Due to confidentiality restrictions, some company names cannot be disclosed. Additional information is available upon request. As of 31 May 2026.
